SUPN · Supernus Pharmaceuticals, Inc.
$48.27
+1.12 (+2.38%)
At close · Aug 14
Market Cap
$2.81B
Shares
58.13M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$48.27
Open$46.70
Day$46.57–48.39
52W close$42.00–57.00
Avg vol 30d965K
Short int4.8M · 8.3% float · 9.5d
Short vol69%
Last earningsJul 22, 2026
DataJan 2020–Aug 2026
Filing10-Q · Aug 3
Up next
Next earnings call
Oct 15, 2026
Est · unconfirmed
· in 9 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 3, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Buy
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Weak
Quant / Vol
High
Market backdrop
VIX 14.3 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−1%
below
Price vs 50-day avg
+4%
above
RSI (14)
55
neutral
MACD trend
Positive
52-week position
42%
mid-range
Momentum
relative strength
1-month return
0%
trailing
6-month return
−5%
trailing
YTD return
−3%
this year
Relative strength
−19%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $46 › 200d $49 — 200d above 50d
Institutional flow
Distributing
-0% holders QoQ · +46 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
8.29% of float · ▼ -0.7% MoM · 9.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
328 holders — near 3-yr high, broad support
Squeeze score
77
high risk · 0–100
Fundamentals
Revenue growth
−4%
Y/Y
EPS growth
−152%
Y/Y
Free cash flow
$46.0M
Balance sheet
$250.8M
net debt
Quant / Vol
risk profile
Volatility
36%
annualized · 1-yr
Max drawdown
−24%
past year
ATR
4.3%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the Earnings Call filed Mar 31, 2026
Total revenues
· full year 2026
$840M – $870M
Prior guidance
period ended
· from the Earnings Call filed Mar 31, 2025
Combined net sales of Trokendi XR and Oxtellar XR
· full year 2025
$65M – $75M
Total revenues
· full year 2025
$600M – $630M
Combined R&D and SG&A expenses
· full year 2025
$435M – $460M
Non-GAAP operating earnings
· full year 2025
$105M – $130M
GAAP operating earnings (loss)
· full year 2025
$-15M – $10M
Guided vs delivered
· last 1 settled
Total revenue
full year 2024
guided $580M – $620M
$661.82M
Beat +10.3%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−1%
Neutral
Price vs 50-day avg
+4%
Bullish
RSI (14)
55
Neutral
MACD trend
Positive
Bullish
52-week position
42%
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $46 › 200d $49 — 200d above 50d
Institutional flow
Distributing
-0% holders QoQ · +46 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
8.29% of float · ▼ -0.7% MoM · 9.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
328 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $42
Now $48 · 42%
Range high $57
vs 200-day avg -1%
vs 50-day avg +4%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Total revenues from commercial products (Non-GAAP) non-GAAP | $379.5M | Six Months Ended June 30, 2026 | — |
|
|
|||
| Total IQVIA prescriptions for Qelbree | 254,824 | Q1 2026 | — |
|
|
|||
| Adjusted operating earnings (non-GAAP) non-GAAP | $158.7M | twelve months ended December 31, 2025 | — |
| Combined revenues of the Company's four growth products | $521.8M | Full Year 2025 | — |
| ONAPGO enrollment forms submitted since launch | 1,800 | since launch through Q4 2025 | — |
| ONAPGO prescribers since launch | 540 | since launch through Q4 2025 | — |
| Total revenues excluding Trokendi XR and Oxtellar XR net sales (non-GAAP) non-GAAP | $635.9M | Year Ended December 31, 2025 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
SUPN
this stock
Supernus Pharmaceuticals, Inc.
|
$2.81B | -2.9% | -3.9% | — | 8.3% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
|
$64.91B | — | — | — | 0.0% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$56.30B | +13.1% | — | — | 0.1% |
|
GALDY
Galderma Group AG/ADR
|
$49.49B | +2.4% | — | — | 0.0% |
|
TEVA
Teva Pharmaceutical Industries Ltd
|
$42.85B | +17.8% | +4.3% | 60.3 | 2.9% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| SUPN | +1.3% | +0.5% | -4.8% | +8.2% | -2.9% |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | +0.9% | -4.0% | -18.5% | +4.2% | -16.7% |
Key facts
CIK
1356576
CUSIP
868459108
13F (30d)
307 filings
303 filers
Visit website
Investor relations